Both Moderna and Pfizer have released early data showing the effectiveness of their vaccines and booster doses as the new omicron variant begins to take hold and as COVID cases rise across the U.S.
But is one performing better than the other?
There are various reasons why someone might choose a particular vaccine, but according to medical experts, the most important thing is getting vaccinated and getting a booster dose.
"The big difference is not which vaccine, it's vaccinated or not vaccinated," Chicago Department of Public Health Commissioner Dr. Allison Arwady said in a Facebook Live earlier this month. "So I hope if there are people who've been waiting, but are now worried with omicron, you know, now definitely is the time."
We're making it easier for you to find stories that matter with our new newsletter — The 4Front. Sign up here and get news that is important for you to your inbox.
Still, it's a question many ask as they prepare for their vaccination or even their booster shots, with mixing and matching now authorized by U.S. regulators.
Here's what we know so far:
Does Pfizer's booster shot protect against omicron?
Pfizer said last week that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective.
Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster increased by 25-fold people's levels of virus-fighting antibodies.
Blood samples taken a month after a booster showed people harbored levels of omicron-neutralizing antibodies that were similar to amounts proven protective against earlier variants after two doses.
Does Moderna's booster shot protect against omicron?
Moderna said Monday its COVID-19 booster does appear to provide protection against the omicron variant.
In an announcement early Monday, the drug company said preliminary data from lab testing found the version of its booster currently in use in the United States and elsewhere provided increased antibody levels to neutralize the virus. But it also found that a double dose of the booster shot provided a much greater increase in those levels.
The drug company said its currently FDA-approved 50 microgram booster was found to increase neutralizing antibody levels against omicron 37-fold compared to pre-boost levels. Meanwhile, it found that a 100 microgram booster dose gave an 83-fold increase in neutralizing antibody levels.
Data on the Johnson & Johnson vaccine is expected to be released this month.
How effective are the vaccines against omicron without a booster?
Vaccine efficacy has been a main question as both the omicron and delta variants continue to spread around the country and the globe.
Health experts have said that a majority of hospitalizations and deaths associated with the delta variant in recent months have largely been in unvaccinated individuals. The CDC has said the risk of infection is 8x higher in the unvaccinated than the vaccinated, and the risk of hospitalization or death is 25x higher.
But is one better than the other at protecting against breakthrough infections in vaccinated populations?
"No vaccine is perfect, for one thing," said Dr. Egon Ozer, who works in infectious diseases at Northwestern Medicine. "No vaccine is going to be a magic bullet. So, especially with so much virus that’s still circulating, there’s always potential that there’s going to be some breakthrough, that people are still going to be able to get some degree of the virus. That’s certainly been the case with delta, as well.”
Scientists don't yet know how big a threat the omicron variant really is or if it will affect protection given from current vaccines, but early signs have shown the variant is more contagious and could decrease some vaccine protection. Currently, the extra-contagious delta variant is responsible for most of the COVID-19 cases in the U.S. and other countries.
In Chicago and multiple Midwestern states, early cases of the omicron variant have appeared in fully vaccinated residents, some of whom also received booster doses, though symptoms have so far remained mild.
The omicron variant, discovered late last month, carries an unusually large number of mutations and scientists are racing to learn how easily it spreads, whether it causes illness that is more serious or milder than other coronavirus types — and how much it might evade the protection of prior vaccinations.
In a small preliminary study out of South Africa, where the omicron variant was first detected, scientists said the variant significantly reduces antibody protection generated by Pfizer and BioNTech's vaccine, although people who have recovered from the virus and received a booster shot will likely have more protection from severe disease.
The findings of the study were first released last week.
In the study, Prof. Alex Sigal with the Africa Health Research Institute and a team of scientists tested blood samples of 12 people who had previously been vaccinated with the Pfizer/BioNTech vaccine. They were looking specifically at how well antibodies generated by the vaccine can neutralize the new variant — meaning block its ability to infect cells.
They found a 41-fold drop in the ability of the antibodies to neutralize the omicron variant compared with the original virus, a dramatic reduction from its performance against the original ancestral strain as well as other variants, according to a preprint of the study that hasn't yet been peer-reviewed. Vaccine-induced antibodies dropped threefold in their ability to neutralize the earlier beta variant that previously dominated South Africa, suggesting omicron is much better at evading protection.
Health experts, including Chicago's top doctor, have said increases in breakthrough infections are possible with the new omicron variant, but early research shows that those who are vaccinated could have milder cases.
"We do think at this point, vaccines are very likely to continue to protect against severe disease, but because there will be probably more transmission that makes it harder to control efforts," Arwady said. "And it puts everybody at some more risk."
At the same time, people who contract a breakthrough infection after receiving the COVID-19 vaccine may acquire a "super immunity" to the virus, researchers from the Oregon Health & Science University found.
A study, which was published in the Journal of the American Medical Association, revealed antibodies in blood samples of those with breakthrough infections were as much as 1,000% times more effective than those generated two weeks following the second dose of the Pfizer vaccine.
As part of the study, blood samples were collected from 52 people, all university employees who received the Pfizer vaccine. A total of 26 people were identified as having mild breakthrough infections following vaccination. Of those cases, 10 involved the highly-contagious delta variant, nine were non-delta and seven were unknown variants, according to the study.
Meanwhile, the risk of suffering a breakthrough COVID-19 infection with the delta variant after being fully vaccinated with the Moderna vaccine may be much lower than the risk for those who received the Pfizer vaccine, according to new Mayo Clinic study released in August.
The study found that in July in Florida, where COVID cases were at an all-time high and the delta variant was prevalent, the risk of a breakthrough case was 60% lower for Moderna recipients as compared to Pfizer recipients.
Similarly, in Minnesota that same month, the authors found that the Moderna vaccine was 76% effective at preventing infection, but the Pfizer vaccine was 42% effective.
The authors of the study found that while both vaccines "strongly protect" against severe disease the delta variant, the difference appears to be more about whether people get infected at all in the first place.
While Moderna's two-dose vaccine remained "durable" six months after the second shot, immunity against the coronavirus will continue to wane and eventually diminish vaccine efficacy, the company has said.
The company said its vaccine is 93% effective six months after the second dose. By comparison, Pfizer and BioNTech said their vaccine efficacy declined to around 84% after six months.
Will there be an omicron-specific booster shot needed?
Pfizer and BioNTech already are working to create an omicron-specific vaccine in case it’s needed.
Moderna's Chief Medical Officer Paul Burton said the vaccine maker could also roll out a reformulated vaccine against the omicron coronavirus variant early next year.
Even after the early findings on its booster, the company said it would still be working to develop an omicron-specific booster, with the shot expected to advance into clinical trials in early 2022.
